Running Oak Capital LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,898 shares of the medical research company's stock after acquiring an additional 9,257 shares during the quarter. Running Oak Capital LLC's holdings in IQVIA were worth $11,967,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in IQV. FMR LLC raised its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA in the third quarter worth about $147,683,000. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in shares of IQVIA by 285.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock valued at $56,783,000 after purchasing an additional 198,808 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
IQVIA Stock Down 0.7 %
Shares of NYSE:IQV traded down $1.46 during trading on Friday, hitting $204.54. 672,987 shares of the company's stock traded hands, compared to its average volume of 1,028,336. The company has a 50-day moving average price of $199.71 and a 200-day moving average price of $221.11. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $37.12 billion, a price-to-earnings ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48.
Analyst Upgrades and Downgrades
A number of brokerages have commented on IQV. Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They issued a "buy" rating and a $276.00 price objective for the company. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. BTIG Research lowered their price target on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, Morgan Stanley cut their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and an average target price of $255.71.
Check Out Our Latest Stock Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
